Pulmonary surfactant in allergic inflammation: New insights into the molecular mechanisms of surfactant function

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 288, Issue 4 32-4, 2005, Pages

  Cochrane, Charles G ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPALMITOYLPHOSPHATIDYLCHOLINE; LUNG SURFACTANT; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITOL; SURFACTANT PROTEIN B;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC PNEUMONITIS; ASTHMA; ATELECTASIS; CLINICAL TRIAL; CORRELATION ANALYSIS; EDITORIAL; HUMAN; INFLAMMATION; LIPID MEMBRANE; LUNG ALVEOLUS; LUNG COLLAPSE; LUNG EDEMA; LUNG VENTILATION; MOLECULAR MECHANICS; PATHOPHYSIOLOGY; PREMATURITY; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; RAMAN SPECTROMETRY; TIDAL VOLUME;

ALLERGENS; ANTIGEN PRESENTATION; ASTHMA; HUMANS; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; PULMONARY SURFACTANTS; SURFACE TENSION;

EID: 15544381789     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.00434.2004     Document Type: Editorial

References (21)

1. Cochrane CG and Revak SD. Pulmonary surfactant protein B (SP-B): structure-function relationships. Science 254: 566-568, 1991.
2. 4-surfactant in preterm infants with RDS. Am J Respir Crit Care Med 153: 404-410, 1996.
3. Ding J, Takamoto DY, von Nahman A, Lipp MM, Lee KYC, Waring AJ, and Zasadzinski JA. Effects of lung surfactant proteins, SP-B and SP-C and palmitic acid on monolayer stability. Biophys J 80: 2262-2272, 2001.
4. Discher BM, Maloney KM, Grainger DW, and Hall SB. Effect of neutral lipids on coexisting phases in monolayers of pulmonary surfactants. Biophys Chem 101-102: 333-345, 2002.
5. Discher BM, Maloney KM, Schief WR Jr, Grainger DW, Vogel V, and Hall SB. Lateral phase separation in interfacial films of pulmonary surfactant. Biophys J 71: 2583-2590, 1996.
6. Gordon LM, Horvath S, Longo M, Zasadzinski JA, Taeusch HW, Faull K, Leung C, and Waring AJ. Conformation and molecular topography of the N-terminal segment of surfactant protein B in structure-promoting environments. Protein Sci 5: 1662-1675, 1996.
7. Hite RD, Seeds MC, Bowton DL, Grier BL, Safta AM, Balkrishnan R, Waite BM, and Bass DA. Surfactant phospholipid changes after antigen challenge: a role for phosphatidylglycerol in dysfunction. Am J Physiol Lung Cell Mol Physiol 288: L610-L617, 2005.
8. 2-mediated surfactant dysfunction. Am J Physiol Lung Cell Mol Physiol 288: L618-L624, 2005.
9. 8a. Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari-Molina A, Kornacka MK, Merritt TA, Segal R, Schaber CJ, Tsai H, Massaro J, D'Agostino R, and Packer M. A double-blind randomized controlled trial of Colfosceril Palmitate, Lucinactant, and Beractant for the prevention of respiratory distress syndrome in very preterm infants. Pediatrics. In press.
10. Oosterlaken-Dijksterhuis MA, Haagsman HP, van Golde LMG, and Demel RA. Interaction of lipid vesicles with monomolecular layers containing lung surfactant proteins SP-B or SP-C. Biochemistry 30: 8276-8281, 1991.
11. Oosterlaken-Dijksterhuis MA, Haagsman HP, van Golde LMG, and Demel RA. Characterization of lipid insertion into monomolecular layers mediated by lung surfactant proteins SP-B and SP-C. Biochemistry 30: 10965-10971, 1991.
12. Piknova B, Schief WR, Vogel V, Discher BM, and Hall SB. Discrepancy between phase behavior of lung surfactant phospholipids and the classical model of surfactant function. Biophys J 81: 2172-2180, 2001.
13. 11a. Poulain FR, Allen L, Williams MC, Hamilton RL, and Hawgood S. Effects of surfactant apolipoproteins on liposome structure: implications for tubular myelin formation. Am J Physiol Lung Cell Mol Physiol 262: L730-L739, 1992.
14. Schief WR, Anitia M, Discher BM, Hall SB, and Vogel V. Liquid-crystalline collapse of pulmonary surfactant monolayers. Biophys J 84: 3792-3806, 2003.
15. Schiller HJ, McCann UG II, Carney DE, Gatto LA, Steinberg JM, and Nieman GF. Altered alveolar mechanisms in the acutely injured lung. Crit Care Med 29: 1049-1055, 2001.
16. 13a. Sinha SK, Lacaze-Masmonteil T, Valls I, Soler A, Wiswell TE, Gadzinowski J, Hajdu J, Bernstein G, Sanchez-Luna M, Segal R, Schaber CJ, Massaro J, and D'Agostino R. A randomized, controlled trial of Lucinactant versus Poractant Alfa in very premature infants at high risk for respiratory distress syndrome. Pediatrics. In press.
17. Taneva S and Keough KMW. Pulmonary surfactant proteins SP-B and SP-C in spread monolayers at the air-water interface: I. Monolayers of pulmonary surfactant protein SP-B and phospholipids. Biophys J 66: 1137-1148, 1994.
18. Taneva S and Keough KMW. Pulmonary surfactant proteins SP-B and SP-C in spread monolayers at the air-water interface: III. Proteins SP-B plus SP-C with phospholipids in spread monolayers. Biophys J 66: 1158-1166, 1994.
19. Vincent JS, Revak SD, Cochrane CG, and Levin IW. Raman spectroscopic studies of model human pulmonary surfactant systems: phospholipid interactions with peptide paradigms for the surfactant protein SP-B. Biochemistry 30: 8395-8401, 1991.
20. Weibel ER and Gil J. Structure-function relationships at the alveolar level. In: Bioengineering Aspects of the Lung, edited by West J. New York: Dekker, 1977.
21. West JB and Wagner PD. Ventilation, blood flow and gas exchange. In: Textbook of Respiratory Medicine (3rd ed.), edited by Murray JF and Nadel JA. Philadelphia, PA: Saunders, 2000, p. 55-89.